FDA endocrine update
Finerenone in type 1 CKD: what the September 2026 label actually says
An indication can expand without making every outcome claim identical. The September 2026 Kerendia label adds CKD associated with type 1 diabetes. Read the exact endpoint and the dosing pathway before borrowing language from type 2 diabetes or heart failure.
Sources checked October 11, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Keep the endpoint attached to the indication
The September 2026 US prescribing information separates three indications. For CKD with type 2 diabetes it names kidney and cardiovascular outcomes. For CKD with type 1 diabetes it names reduction in urinary albumin-to-creatinine ratio (UACR), expected to reduce sustained eGFR decline and end-stage kidney disease. For heart failure with LVEF at least 40%, it names cardiovascular death, hospitalization and urgent heart failure visits.
These statements cannot be merged into one promise. A case asking about type 1 diabetes should not receive the type 2 cardiovascular-outcome wording as though the label had established the same endpoint in both populations. Identify the population and distinguish an observed surrogate endpoint from the outcomes the label expects it to affect.
Screen potassium and kidney function before the first dose
Measure serum potassium and eGFR before initiation. Do not initiate if serum potassium is above 5.0 mEq/L. The starting-dose table gives 20 mg once daily for eGFR at least 60 mL/min/1.73 m2 and 10 mg once daily for eGFR at least 25 but below 60. Initiation below 25 is not recommended.
A new indication does not remove these safety checks. An eligible disease category and an acceptable initiation profile are separate questions. Recover actual laboratory results, their dates and relevant medicines before interpreting a proposed prescription.
Use the CKD dose-adjustment table, not the heart failure target
For CKD associated with type 1 or type 2 diabetes, the target is 20 mg once daily. Measure potassium four weeks after initiation or dose adjustment and periodically thereafter, applying the CKD potassium table. The heart failure pathway may target 20 or 40 mg and has its own adjustment table.
Do not promote every patient to 40 mg because that strength appears in the highlights. A strength, a starting dose and an indication-specific target are different facts. The source checked here is revised September 2026; an older July 2025 label omits the new type 1 CKD indication.
Check interactions independently of the indication
Strong CYP3A4 inhibitors are contraindicated; strong or moderate CYP3A4 inducers should be avoided. The label also contraindicates use in adrenal insufficiency and advises avoiding grapefruit or grapefruit juice. Medicines that raise potassium require attention to monitoring.
For an exam case, explain both the disease match and the reason a proposed start or increase is unsafe. In practice, prescribing decisions need the full current label and clinical assessment. This lesson does not turn UACR reduction into a guaranteed long-term outcome for an individual.
A worked case
An adult with CKD associated with type 1 diabetes has eGFR 48 and potassium 5.2. A draft plan starts Kerendia 20 mg and claims proven reduction in cardiovascular death in this type 1 CKD population. What needs correcting?
- The type 1 CKD indication uses UACR reduction and expected kidney benefit, not the type 2 outcome wording.
- Potassium above 5.0 prevents initiation under the label.
- If initiation later becomes appropriate, eGFR 48 corresponds to the 10 mg starting-dose band, not 20 mg.
Answer: Do not approve the proposed start. Correct the endpoint claim and resolve potassium and the actual initiation plan with the clinical team.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Does the type 1 CKD indication use the same endpoint wording as type 2 CKD?
No. It states UACR reduction expected to reduce kidney decline and end-stage kidney disease.
2. Can treatment start at potassium 5.2 mEq/L?
No. The label says not to initiate above 5.0.
3. Is 40 mg the CKD target for every indication?
No. The CKD target is 20 mg once daily; the heart failure pathway differs.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.